Gilead Sciences/$GILD
GILD rises after raising its full-year adjusted EPS guidance to $7.95–$8.25 on stronger-than-expected Q2 HIV drug sales.
3 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Health
Primary listing
Employees
17,600
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$137B
22.01
$5.01
-
$3.12
2.87%
Price and volume
Market cap
$137B
52-week high
$119.96
52-week low
$72.43
Average daily volume
6.3M
Dividend rate
$3.12
Financial strength
Current ratio
1.315
Quick ratio
0.893
Long term debt to equity
113.017
Total debt to equity
127.34
Dividend payout ratio (TTM)
62.75%
Interest coverage (TTM)
10.99%
Profitability
EBITDA (TTM)
13,751
Gross margin (TTM)
78.53%
Net profit margin (TTM)
21.87%
Operating margin (TTM)
38.05%
Effective tax rate (TTM)
12.36%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
12.56%
Return on equity (TTM)
33.40%
Valuation
Price to earnings (TTM)
22.007
Price to revenue (TTM)
4.763
Price to book
6.96
Price to tangible book (TTM)
-19.01
Price to free cash flow (TTM)
14.672
Free cash flow yield (TTM)
6.82%
Free cash flow per share (TTM)
7.516
Dividend yield (TTM)
2.83%
Forward dividend yield
2.87%
Growth
Revenue change (TTM)
3.81%
Earnings per share change (TTM)
496.80%
3-year revenue growth (CAGR)
1.61%
10-year revenue growth (CAGR)
-0.11%
3-year earnings per share growth (CAGR)
15.28%
10-year earnings per share growth (CAGR)
-6.17%
3-year dividend per share growth (CAGR)
2.26%
10-year dividend per share growth (CAGR)
21.76%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Sept15
Gilead Sciences
Dividend·Ex-dividend
Sept29
Gilead Sciences
Dividend·Payment
$0.79Per share
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $137B as of August 08, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 22.01 as of August 08, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of August 08, 2025, the dividend rate is $3.12 and the yield is 2.87%. Gilead Sciences has a payout ratio of 62.75% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment is scheduled for September 29, 2025.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) does not currently have a Beta indicator.